CN101914134B - 人乳头瘤58型病毒e7蛋白的线性抗原表位最小基序肽 - Google Patents
人乳头瘤58型病毒e7蛋白的线性抗原表位最小基序肽 Download PDFInfo
- Publication number
- CN101914134B CN101914134B CN 201010259028 CN201010259028A CN101914134B CN 101914134 B CN101914134 B CN 101914134B CN 201010259028 CN201010259028 CN 201010259028 CN 201010259028 A CN201010259028 A CN 201010259028A CN 101914134 B CN101914134 B CN 101914134B
- Authority
- CN
- China
- Prior art keywords
- peptide
- hpv58
- epitope
- minimum motif
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 124
- 108090000623 proteins and genes Proteins 0.000 title abstract description 21
- 102000004169 proteins and genes Human genes 0.000 title abstract description 19
- 241000701784 Human papillomavirus type 58 Species 0.000 title description 68
- 239000000427 antigen Substances 0.000 claims abstract description 14
- 102000036639 antigens Human genes 0.000 claims abstract description 14
- 108091007433 antigens Proteins 0.000 claims abstract description 14
- 241000700605 Viruses Species 0.000 claims abstract description 8
- 238000001514 detection method Methods 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 238000005267 amalgamation Methods 0.000 claims description 15
- 241000701806 Human papillomavirus Species 0.000 abstract description 52
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 36
- 210000002966 serum Anatomy 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 229940023041 peptide vaccine Drugs 0.000 abstract description 3
- 238000011895 specific detection Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 239000000969 carrier Substances 0.000 abstract 1
- 230000004727 humoral immunity Effects 0.000 abstract 1
- 231100000590 oncogenic Toxicity 0.000 abstract 1
- 230000002246 oncogenic effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 125000000539 amino acid group Chemical group 0.000 description 12
- 239000012530 fluid Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000013016 damping Methods 0.000 description 9
- 230000004927 fusion Effects 0.000 description 8
- 238000013507 mapping Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- HKEZZWQWXWGASX-KKUMJFAQSA-N Asp-Leu-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HKEZZWQWXWGASX-KKUMJFAQSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000341655 Human papillomavirus type 16 Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000011587 new zealand white rabbit Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- OEDPLIBVQGRKGZ-AVGNSLFASA-N Cys-Tyr-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O OEDPLIBVQGRKGZ-AVGNSLFASA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000005201 scrubbing Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000004340 zona pellucida Anatomy 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- CZPAHAKGPDUIPJ-CIUDSAMLSA-N Ala-Gln-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CZPAHAKGPDUIPJ-CIUDSAMLSA-N 0.000 description 1
- IDUUACUJKUXKKD-VEVYYDQMSA-N Asn-Pro-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O IDUUACUJKUXKKD-VEVYYDQMSA-N 0.000 description 1
- VILLWIDTHYPSLC-PEFMBERDSA-N Asp-Glu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VILLWIDTHYPSLC-PEFMBERDSA-N 0.000 description 1
- HAFCJCDJGIOYPW-WDSKDSINSA-N Asp-Gly-Gln Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O HAFCJCDJGIOYPW-WDSKDSINSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- YZFCGHIBLBDZDA-ZLUOBGJFSA-N Cys-Asp-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YZFCGHIBLBDZDA-ZLUOBGJFSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 101150071673 E6 gene Proteins 0.000 description 1
- 101150013359 E7 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- NNQHEEQNPQYPGL-FXQIFTODSA-N Gln-Ala-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O NNQHEEQNPQYPGL-FXQIFTODSA-N 0.000 description 1
- ITBHUUMCJJQUSC-LAEOZQHASA-N Glu-Ile-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O ITBHUUMCJJQUSC-LAEOZQHASA-N 0.000 description 1
- SWDNPSMMEWRNOH-HJGDQZAQSA-N Glu-Pro-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWDNPSMMEWRNOH-HJGDQZAQSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- CIMULJZTTOBOPN-WHFBIAKZSA-N Gly-Asn-Asn Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CIMULJZTTOBOPN-WHFBIAKZSA-N 0.000 description 1
- YTSVAIMKVLZUDU-YUMQZZPRSA-N Gly-Leu-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YTSVAIMKVLZUDU-YUMQZZPRSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 241000780272 Mammilla Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- SGCZFWSQERRKBD-BQBZGAKWSA-N Pro-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 SGCZFWSQERRKBD-BQBZGAKWSA-N 0.000 description 1
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 1
- FDMCIBSQRKFSTJ-RHYQMDGZSA-N Pro-Thr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O FDMCIBSQRKFSTJ-RHYQMDGZSA-N 0.000 description 1
- FTVRVZNYIYWJGB-ACZMJKKPSA-N Ser-Asp-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FTVRVZNYIYWJGB-ACZMJKKPSA-N 0.000 description 1
- KCFKKAQKRZBWJB-ZLUOBGJFSA-N Ser-Cys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O KCFKKAQKRZBWJB-ZLUOBGJFSA-N 0.000 description 1
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- NLSNVZAREYQMGR-HJGDQZAQSA-N Thr-Asp-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NLSNVZAREYQMGR-HJGDQZAQSA-N 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 229940125667 peptide vaccine candidate Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical group C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 1
- 238000010023 transfer printing Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010259028 CN101914134B (zh) | 2010-08-17 | 2010-08-17 | 人乳头瘤58型病毒e7蛋白的线性抗原表位最小基序肽 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010259028 CN101914134B (zh) | 2010-08-17 | 2010-08-17 | 人乳头瘤58型病毒e7蛋白的线性抗原表位最小基序肽 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101914134A CN101914134A (zh) | 2010-12-15 |
CN101914134B true CN101914134B (zh) | 2013-06-19 |
Family
ID=43321800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010259028 Expired - Fee Related CN101914134B (zh) | 2010-08-17 | 2010-08-17 | 人乳头瘤58型病毒e7蛋白的线性抗原表位最小基序肽 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101914134B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109486842A (zh) * | 2017-09-12 | 2019-03-19 | 上海市计划生育科学研究所 | 短肽重组克隆构建筛选的载体及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006031063A1 (en) * | 2004-09-15 | 2006-03-23 | Sigmol, Inc. | Protein cleavage at aspartic acid using chemical reagents |
CN101696231A (zh) * | 2009-09-29 | 2010-04-21 | 上海市计划生育科学研究所 | 人乳头瘤病毒58型e6蛋白的抗原表位最小基序肽 |
-
2010
- 2010-08-17 CN CN 201010259028 patent/CN101914134B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006031063A1 (en) * | 2004-09-15 | 2006-03-23 | Sigmol, Inc. | Protein cleavage at aspartic acid using chemical reagents |
CN101696231A (zh) * | 2009-09-29 | 2010-04-21 | 上海市计划生育科学研究所 | 人乳头瘤病毒58型e6蛋白的抗原表位最小基序肽 |
Non-Patent Citations (4)
Title |
---|
Paul K. S. Chan等.T-Cell Response to Human Papillomavirus Type 58 L1, E6, and E7 Peptides in Women with Cleared Infection, Cervical Intraepithelial Neoplasia, or Invasive Cancer.《CLINICAL AND VACCINE IMMUNOLOGY》.2010, American Society for Microbiology,2010,第17卷(第9期),第1315-1321页. * |
宋敬东等.人乳头瘤病毒疫苗的研究进展.《中国生物工程杂志》.2007,第27卷(第4期),第104-109页. * |
徐云飞等.人乳头瘤病毒16E7抗原细胞毒性T细胞预测表位合成肽的纯化与鉴定.《中华皮肤科杂志》.2003,第36卷(第5期),第284页. * |
董金蓉等.人乳头瘤病毒的病原免疫学及其疫苗的研究进展.《微生物学免疫学进展》.2007,第35卷(第3期),第74-79页. * |
Also Published As
Publication number | Publication date |
---|---|
CN101914134A (zh) | 2010-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR870000702B1 (ko) | 합성 항원 펩티드의 제조방법 | |
EP0217919B1 (en) | Type-specific papillomavirus dna sequences and peptides | |
AU615159B2 (en) | Determined dna sequences derived from a papillomavirus genome, their uses for in vitro diagnostic purposes and the production of antigenic compositions | |
Lin et al. | Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product | |
US5665535A (en) | Polypeptides encoded by DNA sequences derived from the genome of the papillomavirus HPV39, antibodies thereto, and their use in in vitro diagnosis | |
EP2522756A2 (en) | Method of producing an HPV protein using affinity chromatography | |
Luevano et al. | High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays | |
Jenkins et al. | An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16 | |
WO2008098484A1 (fr) | Protéines l1 recombinantes du papillomavirus et leurs utilisations | |
CN101153059B (zh) | 用于鼻咽癌筛查、诊断和治疗效果预测的elisa试剂盒 | |
CA2411945A1 (en) | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor | |
CN103342738B (zh) | 人乳头瘤病毒e6蛋白可诱发同源蛋白间交叉反应性抗体的精细表位肽 | |
DK172647B1 (da) | Samling af polypeptider og samling af antistoffer, som er karakteristiske for papillomavirus, og diagnostiske metoder, hvor | |
Tyler et al. | Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing | |
US5981173A (en) | Genital human papillomavirus type 68a (HPV-68a), related to the potentially oncogenic HPV-39 | |
CN101696231B (zh) | 人乳头瘤病毒58型e6蛋白的抗原表位最小基序肽 | |
CN102558313A (zh) | 肠道病毒71型特异性重组蛋白抗原及其应用 | |
CN101962400B (zh) | 人乳头瘤58型病毒l1蛋白的线性抗原表位最小基序肽及其应用 | |
CN101220085B (zh) | 人巨细胞病毒重组蛋白质及其制备方法 | |
Köchel et al. | Antibodies to human papillomavirus type-16 in human sera as revealed by the use of prokaryotically expressed viral gene products | |
CN101914134B (zh) | 人乳头瘤58型病毒e7蛋白的线性抗原表位最小基序肽 | |
WO2014127741A1 (zh) | 可用于检测抗人乳头瘤病毒抗体的抗原、试剂盒及其应用 | |
US8715681B2 (en) | Minimal motifs of linear B-cell epitopes in L1 protein from human papillomavirus type 58 and their applications | |
Yaegashi et al. | Sequence and antigenic diversity in two immunodominant regions of the L2 protein of human papillomavirus types 6 and 16 | |
Moro et al. | Bacterial expression and immunological detection of human papillomavirus type 16 E7 protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: LIU RITING Free format text: FORMER OWNER: SHANGHAI FAMILY PLANNING SCIENCE AND RESEARCH INSTITUTE. Effective date: 20120420 Free format text: FORMER OWNER: FUDAN UNIVERSITY Effective date: 20120420 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200032 XUHUI, SHANGHAI TO: 510310 GUANGZHOU, GUANGDONG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20120420 Address after: 510310 Guangdong city of Guangzhou province Haizhuqu District Chigang Street No. 22 Room 204 Applicant after: Liu Riting Address before: 200032 Shanghai Xuhui District Xietu Road No. 2140 Applicant before: Shanghai Institute of Planned Parenthood Research Co-applicant before: Fudan University |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU HENGSHANG MEDICINE TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LIU RITING Effective date: 20131225 Owner name: LIU RITING Effective date: 20131225 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510310 GUANGZHOU, GUANGDONG PROVINCE TO: 510006 GUANGZHOU, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131225 Address after: 510006 Guangdong city of Guangzhou province Panyu District Xiaoguwei Street Outer Ring Road No. 280 (Guangdong Pharmaceutical University Department building) room 208 Patentee after: Guangzhou Hengshang Medical Technology Co., Ltd. Patentee after: Liu Riting Address before: 510310 Guangdong city of Guangzhou province Haizhuqu District Chigang Street No. 22 Room 204 Patentee before: Liu Riting |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170421 Address after: 510310 Guangdong city of Guangzhou province Haizhuqu District Chigang Street No. 22 Room 204 Patentee after: Gao Xiang Address before: 510006 Guangdong city of Guangzhou province Panyu District Xiaoguwei Street Outer Ring Road No. 280 (Guangdong Pharmaceutical University Department building) room 208 Co-patentee before: Liu Riting Patentee before: Guangzhou Hengshang Medical Technology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171115 Address after: 511401 Guangdong city of Guangzhou province Panyu District city town Kang Ping Road No. 57-63 No. 1207 Zhujiang Trading Center Patentee after: Guangdong South Bay Medical Technology Co., Ltd. Address before: 510310 Guangdong city of Guangzhou province Haizhuqu District Chigang Street No. 22 Room 204 Patentee before: Gao Xiang |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130619 Termination date: 20180817 |
|
CF01 | Termination of patent right due to non-payment of annual fee |